[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100440383":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":36,"locations":44,"responsibleParty":118,"collaborators":121,"id":124,"slug":125,"hasResults":126,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":126,"sex":132,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":18,"studyType":138,"phases":139,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":74,"whyStopped":18,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},{"fullName":5,"class":6},"University of Turin, Italy","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Pre-emptive vasopressor","EXPERIMENTAL","Pre-emptive continuous infusion of norepinephrine during intubation",[13],"Drug: Noradrenaline",{"label":15,"type":16,"description":17,"interventionNames":18},"No vasopressor","NO_INTERVENTION","No pre-emptive administration of vasopressors",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Noradrenaline","Pre-emptive continuous infusion of noradrenaline during the peri-intubation period",[9],[26],"Norepinephrine",[28,32],{"name":29,"affiliation":30,"role":31},"Vincenzo Russotto, MD","University Hospital San Luigi Gonzaga","PRINCIPAL_INVESTIGATOR",{"name":33,"affiliation":34,"role":35},"John G Laffey, MD","University Hospital Galway, NUI Galway, Ireland","STUDY_CHAIR",[37,41],{"name":29,"role":38,"phone":39,"phoneExt":18,"email":40},"CONTACT","+393297893044","vincenzo.russotto@unito.it",{"name":42,"role":38,"phone":18,"phoneExt":18,"email":43},"Antonella Vasamì","antonella.vasami@marionegri.it",[45,60,72,87,100,110],{"facility":46,"status":47,"city":48,"state":18,"zip":18,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"CHU de Nantes","NOT_YET_RECRUITING","Nantes","France","FR",{"type":52,"coordinates":53},"Point",[54,55],-1.55336,47.21725,{"lat":55,"lon":54},[58],{"name":59,"role":38,"phone":18,"phoneExt":18,"email":18},"Jean Baptiste Lascarrou, MD, PhD",{"facility":61,"status":47,"city":62,"state":18,"zip":18,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Galway University Hospitals","Galway","Ireland","IE",{"type":52,"coordinates":66},[67,68],-9.05095,53.27245,{"lat":68,"lon":67},[71],{"name":33,"role":38,"phone":18,"phoneExt":18,"email":18},{"facility":73,"status":74,"city":75,"state":76,"zip":18,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Humanitas Research Hospital","RECRUITING","Rozzano","Milan","Italy","IT",{"type":52,"coordinates":80},[81,82],9.1559,45.38193,{"lat":82,"lon":81},[85],{"name":86,"role":38,"phone":18,"phoneExt":18,"email":18},"Alessandro Protti",{"facility":30,"status":47,"city":88,"state":89,"zip":90,"country":77,"countryCode":78,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Orbassano","Turin","10043",{"type":52,"coordinates":92},[93,94],7.53813,45.00547,{"lat":94,"lon":93},[97,98],{"name":29,"role":38,"phone":18,"phoneExt":18,"email":40},{"name":99,"role":38,"phone":18,"phoneExt":18,"email":18},"Pietro Caironi, MD",{"facility":101,"status":74,"city":76,"state":18,"zip":18,"country":77,"countryCode":78,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"ASST Grande Ospedale Metropolitano Niguarda",{"type":52,"coordinates":103},[104,105],9.18951,45.46427,{"lat":105,"lon":104},[108],{"name":109,"role":38,"phone":18,"phoneExt":18,"email":18},"Thomas Langer",{"facility":111,"status":74,"city":76,"state":18,"zip":18,"country":77,"countryCode":78,"cosmosGeoPoint":112,"geoPoint":114,"contacts":115},"Policlinico di Milano",{"type":52,"coordinates":113},[104,105],{"lat":105,"lon":104},[116],{"name":117,"role":38,"phone":18,"phoneExt":18,"email":18},"Giacomo Grasselli",{"type":31,"investigatorFullName":119,"investigatorTitle":120,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Vincenzo Russotto","Principal Investigator",[122],{"name":123,"class":6},"Istituto Di Ricerche Farmacologiche Mario Negri","100440383","phase-3-preventing-cardiovascular-collapse-with-vasopressors-during-tracheal-intubation-100440383",false,"NCT05014581","Preventing Cardiovascular Collapse With Vasopressors During Tracheal Intubation","Preventing Cardiovascular Collapse With Vasopressors During Tracheal Intubation. The PREVENTION Randomized Multicenter Study","PREVENTION","Inclusion Criteria:\n\n* Patient is admitted or scheduled for admission to a participating study hospital\n* Planned procedure is tracheal intubation and planned operator is a provider expected to routinely perform endotracheal intubation in the participating unit\n* Critical illness (i.e. life-threatening condition with intubation required for cardiorespiratory failure or neurological impairment)\n* Administration of sedation (with or without neuromuscular blockade) is planned\n* Age 18 years or older\n\nExclusion Criteria:\n\n* No vasopressors\u002Finotropes at the moment of screening for eligibility\n* MAP \\\u003C 60 mmHg or \\> 120 mmHg at the moment of screening for eligibility\n* Urgency of intubation precludes safe performance of study procedures\n* Intubation performed during cardiopulmonary resuscitation of a patient in cardiac arrest\n* Enrolled in another clinical trial that is unapproved for co-enrollment\n* Pregnant or suspected pregnancy","ALL","18 Years","90 Years",{"count":136,"type":137},420,"ESTIMATED","INTERVENTIONAL",[140],"PHASE3","Tracheal intubation (TI) is associated with a high risk of adverse events in critically ill patients and peri-intubation hemodynamic collapse is the most commonly observed. The primary aim of the PREVENTION trial is to compare the effect of the pre-emptive use of noradrenaline versus no peri-intubation use of noradrenaline on incidence of cardiovascular collapse following TI in adult critically ill patients. Patients with absolute indication or contraindication to vasopressor support will be excluded from this trial. Patients will be randomized 1:1 to a continuous infusion of noradrenaline started before induction titrated according to baseline mean arterial pressure. The primary outcome will be the incidence of cardiovascular collapse. Secondary outcomes will include lowest systolic blood pressure and cardiac arrest within 30 minutes from intubation.",[143,144],"Critical Illness","Respiratory Failure",[146],"tracheal intubation","2025-03-24",{"date":149,"type":150},"2025-03-28","ACTUAL",{"date":152,"type":150},"2024-08-01",{"date":154,"type":137},"2026-04",{"name":5,"class":6},6]